10-Q · May 14, 2026
Eton Pharmaceuticals delivered a strong performance in Q1 2026 with total revenues increasing to $24.27 million, up from $17.28 million year-over-year. The company's diluted EPS improved to $0.14 compared to a loss of…
Earnings analysis · 10-Q
ETON earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Eton delivered a strong Q2, with revenue of $37.568 million and diluted EPS of $0.43, materially above consensus and sharply improved versus both the prior quarter and prior-year period. Operating margin reached 34.0%…
Read full summary
Eton delivered a strong Q2, with revenue of $37.568 million and diluted EPS of $0.43, materially above consensus and sharply improved versus both the prior quarter and prior-year period. Operating margin reached 34.0% and adjusted EBITDA margin was 43%, while management raised full-year revenue and EBITDA margin expectations. The principal offset is $27.0 million of variable-rate debt, alongside up to $7 million of identified ASN-001 and ALKINDI-related costs.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.43
- Operating margin
- 34.0%
What stood out
-
Revenue growth and major consensus beat
Q2 revenue was $37.568 million, up approximately 56% from $24 million in Q1 2026 and approximately 98% from $19 million in Q2 2025. Revenue exceeded the $27.139 million consensus estimate by approximately 38%.
-
EPS turned strongly positive
Diluted EPS was $0.43 versus $0.05 in Q1 2026 and a $(0.10) loss in Q2 2025. EPS exceeded the $0.18 consensus estimate by $0.25.
-
Operating profitability expanded
GAAP operating margin expanded to 34.0%, compared with 9.9% in Q1 2026 and negative 7.8% in Q2 2025, indicating substantial operating leverage.
-
EBITDA margin exceeded raised target
Adjusted EBITDA margin reached 43%, above the company’s increased full-year 2026 target of at least 35%.
-
Full-year outlook raised
The company raised 2026 revenue expectations to more than $145 million from more than $120 million and raised adjusted EBITDA margin expectations to at least 35% from at least 30%.
-
No reported control deficiencies
Disclosure controls were concluded effective as of June 30, 2026, and the company reported no changes in internal controls that materially affected or were reasonably likely to materially affect financial reporting.
What to watch
-
Variable-rate debt and interest exposure
The company had $27.0 million of borrowings outstanding under its variable-rate credit agreement as of June 30, 2026, with interest indexed to SOFR plus 6.55%, creating exposure to higher interest expense.
-
Pipeline and milestone cash costs
The 2026 outlook includes a $3 million ASN-001 licensing expense and a potential $4 million ALKINDI SPRINKLE milestone payment, which could pressure near-term earnings and cash flow if incurred.
-
Warrant-related dilution without proceeds
The company issued 296,215 common shares through cashless warrant exercises during the quarter; 62,901 warrants were surrendered and the company received no cash proceeds, creating dilution without a financing inflow.
-
No new formal risk-factor additions
The filing states that no new risk factors were identified relative to the 2025 10-K; however, the company remains exposed to institutional concentration and investment risks, including cash deposits and a government money market fund as of June 30, 2026.
Management's outlook
Management raised 2026 revenue outlook to more than $145 million from more than $120 million and increased adjusted EBITDA margin guidance to at least 35% from at least 30%. The outlook includes a $3 million ASN-001 licensing expense and a potential $4 million ALKINDI SPRINKLE milestone payment.
Earlier filings 4
10-K · March 19, 2026
Eton positions itself as a rare-disease specialty pharma with an acquisitive, BD-led strategy: 8 commercial products and five late-stage candidates (including ET-600 with a PDUFA date of February 25, 2026). Recent…
10-Q · November 6, 2025
Eton reported Q3 2025 revenue of $22,459,000 (vs. $10,324,000 in Q3 2024) and gross profit of $7,855,000, but recorded a GAAP net loss of $1,927,000 (GAAP EPS $(0.07) basic). Operating results reflect higher R&D and G&A…
10-Q · May 13, 2025
Eton Pharmaceuticals reported Q1 2025 results showing a significant increase in total revenues to $17.28 million, up from $7.97 million in Q1 2024. The gross margin decreased slightly to 57.1% from 62.9% in the prior…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.